Aims & Scope:
Multifactorial diseases, such as cancer, neurodegenerative disorders, diabetes and others, are difficult to be treated with drugs with act in a single target. Combinations of drugs that act in different targets can achieve additive or synergic effects in the disease management and offers some advantages regarding efficacy, less adverse effects and lower chance of resistance development. The rational design of multitarget ligands is a widely used strategy in the drug discovery. This thematic issue aims to cover advances in the development of multitarget therapeutics for the treatment of cancer, diabetes, cardiovascular disorders, malaria and other diseases. We will cover an update in the rational use of the molecular hybridization strategy for the generation of multitarget ligands. Structure-based and machine learning methods will be addressed for the development of multitarget ligands.

Keywords: Multitarget ligands, Medicinal chemistry, and Drug design

Subtopics:
The subtopics to be covered within this issue are listed below:

- Advances in the development of multitarget therapeutics for the treatment of cancer, diabetes, cardiovascular diseases and other diseases;
- Rational use of the molecular hybridization strategy;
- Structure-based and machine learning methods will be addressed for the development of multi-target ligands;
- New strategies in the use of multitarget ligands.

Schedule:
- Manuscript submission deadline: 10/05/2021
- Peer Review Due: 18/06/2021
- Revision Due: 18/07/2021
- Announcement of acceptance by the Guest Editors: 25/07/2021
- Final manuscripts due: 31/07/2021

Contacts:

Guest Editor Dr. Daniel Alencar Rodrigues
ORCID: https://orcid.org/0000-0001-7898-7093
Affiliation: Royal College of Surgeons in Ireland (RCSI)
Email: danielalencar@rcsi.com, dar.go.qfm@gmail.com

Any queries should be addressed to ctmc@benthamscience.net.